There's no real news or stories this AM that I'm interested in.
APOL is down 12% in the pre-mkt on 13k shares trading after posting disappointing earnings. The options were pricing in a move of 9.6% after closing with IV at 76%. It's a post earnings mover, making an average move of 6.5% with a max move of 10% and a min of 3.8%. There are no weekly options available, however.
Alexion Pharmaceuticals Inc.
shares fell 4.8% to $179 in
late trading after the company said a phase 2 clinical trial of
eculizumab -- a drug to help prevent rejection of kidney transplants -- failed to meet its “primary composite endpoint.”